ArticleInfection and drug resistance2026
Clinical Distribution Characteristics and Antimicrobial Resistance Trends of
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the distribution and antimicrobial susceptibility of Methods: The non-repetitive bacterial strains were detected and collected in this hospital, Pathogen identification was performed using a mass spectrometer. Susceptibility testing was performed using an automated system or disk diffusion. The 2025 CLSI clinical standards were applied to determine susceptibility. Experimental susceptibility data were statistically analyzed using WHONET 5.6 software and SPSS26.0. Chi-square tests and trend tests were used for the statistical analyses. Results: 8992 pathogenic strains were isolated during 2021-2025, including 1135 KPN, and the total detection rate was 12.6%. The annual detection rates from 2021 to 2025 were 12.8% (225/1,756), 11.7% (203/1,733), 14.5% (261/1,804), 12.6% (234/1,863), and 11.5% (212/1,836), respectively. The overall detection rate of Carbapenem-resistant Conclusion: During the five-year period from 2021 to 2025, the isolated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.